Concepts (207)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 18 | 2024 | 827 | 3.240 |
Why?
|
| T-Lymphocytes | 21 | 2024 | 1710 | 2.930 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 14 | 2025 | 1198 | 2.730 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2024 | 539 | 1.900 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2021 | 140 | 1.330 |
Why?
|
| Lymphocyte Transfusion | 2 | 2021 | 57 | 1.250 |
Why?
|
| Antigens, CD19 | 4 | 2024 | 178 | 1.220 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2023 | 482 | 1.080 |
Why?
|
| Lymphoma | 3 | 2024 | 322 | 1.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2018 | 163 | 1.010 |
Why?
|
| Multiple Myeloma | 3 | 2022 | 169 | 0.940 |
Why?
|
| Graft vs Host Disease | 3 | 2024 | 544 | 0.890 |
Why?
|
| Hematologic Neoplasms | 2 | 2024 | 284 | 0.880 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2022 | 144 | 0.850 |
Why?
|
| Hodgkin Disease | 4 | 2022 | 294 | 0.830 |
Why?
|
| Salvage Therapy | 2 | 2021 | 192 | 0.810 |
Why?
|
| Leukemia | 2 | 2024 | 369 | 0.800 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2024 | 502 | 0.800 |
Why?
|
| Cell- and Tissue-Based Therapy | 5 | 2023 | 158 | 0.730 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 30 | 0.730 |
Why?
|
| Bone Marrow | 2 | 2024 | 324 | 0.700 |
Why?
|
| Cyclin A1 | 1 | 2020 | 4 | 0.680 |
Why?
|
| Leukemia, Myeloid | 1 | 2020 | 85 | 0.660 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 259 | 0.650 |
Why?
|
| Adoptive Transfer | 2 | 2020 | 237 | 0.640 |
Why?
|
| Antigens, Neoplasm | 4 | 2024 | 386 | 0.640 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 767 | 0.590 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 85 | 0.580 |
Why?
|
| Transplantation, Homologous | 5 | 2024 | 662 | 0.560 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2017 | 40 | 0.540 |
Why?
|
| Neoplasms | 4 | 2024 | 2773 | 0.520 |
Why?
|
| Humans | 50 | 2025 | 124592 | 0.510 |
Why?
|
| Immunotherapy | 5 | 2024 | 670 | 0.490 |
Why?
|
| Virus Diseases | 3 | 2023 | 279 | 0.470 |
Why?
|
| Niacinamide | 1 | 2013 | 22 | 0.420 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 48 | 0.400 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 5 | 0.370 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2011 | 18 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1139 | 0.360 |
Why?
|
| Combined Modality Therapy | 5 | 2021 | 1232 | 0.340 |
Why?
|
| Recurrence | 3 | 2024 | 1420 | 0.330 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 183 | 0.330 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1214 | 0.310 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 1660 | 0.290 |
Why?
|
| Tissue Donors | 2 | 2021 | 495 | 0.290 |
Why?
|
| Remission Induction | 3 | 2020 | 300 | 0.280 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 1089 | 0.270 |
Why?
|
| Lymphocyte Activation | 2 | 2019 | 692 | 0.270 |
Why?
|
| Herpesvirus 4, Human | 3 | 2024 | 676 | 0.250 |
Why?
|
| Adult | 16 | 2025 | 29435 | 0.240 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 298 | 0.230 |
Why?
|
| Glypicans | 1 | 2024 | 39 | 0.230 |
Why?
|
| Carboplatin | 1 | 2024 | 76 | 0.230 |
Why?
|
| Alemtuzumab | 1 | 2024 | 88 | 0.230 |
Why?
|
| Deoxycytidine | 1 | 2024 | 78 | 0.220 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 931 | 0.220 |
Why?
|
| Interleukin-15 | 1 | 2024 | 92 | 0.220 |
Why?
|
| Male | 19 | 2025 | 61194 | 0.220 |
Why?
|
| Allografts | 2 | 2022 | 192 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12324 | 0.220 |
Why?
|
| T-Cell Antigen Receptor Specificity | 2 | 2021 | 58 | 0.220 |
Why?
|
| Lymphoma, T-Cell | 1 | 2024 | 64 | 0.210 |
Why?
|
| Quinazolines | 1 | 2024 | 174 | 0.210 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 76 | 0.210 |
Why?
|
| Middle Aged | 15 | 2024 | 26712 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2022 | 325 | 0.200 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 1312 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 218 | 0.200 |
Why?
|
| Vulnerable Populations | 1 | 2023 | 140 | 0.190 |
Why?
|
| Antiviral Agents | 2 | 2024 | 748 | 0.190 |
Why?
|
| Hematopoiesis | 1 | 2023 | 215 | 0.190 |
Why?
|
| Young Adult | 8 | 2025 | 9012 | 0.190 |
Why?
|
| Lymphocytes | 1 | 2023 | 406 | 0.190 |
Why?
|
| Aged | 10 | 2024 | 19700 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 338 | 0.180 |
Why?
|
| Genetic Engineering | 2 | 2019 | 160 | 0.180 |
Why?
|
| Ki-1 Antigen | 1 | 2020 | 28 | 0.170 |
Why?
|
| Demography | 1 | 2021 | 240 | 0.170 |
Why?
|
| Prognosis | 4 | 2021 | 4624 | 0.170 |
Why?
|
| Immunologic Factors | 1 | 2021 | 174 | 0.170 |
Why?
|
| Immunity, Cellular | 2 | 2017 | 205 | 0.160 |
Why?
|
| Chromatin | 1 | 2022 | 551 | 0.160 |
Why?
|
| Th1 Cells | 1 | 2020 | 153 | 0.160 |
Why?
|
| Lymphocyte Depletion | 3 | 2024 | 123 | 0.150 |
Why?
|
| Lentivirus | 1 | 2018 | 82 | 0.150 |
Why?
|
| DNA Virus Infections | 1 | 2017 | 22 | 0.140 |
Why?
|
| Parainfluenza Virus 3, Human | 1 | 2017 | 12 | 0.140 |
Why?
|
| Respirovirus Infections | 1 | 2017 | 19 | 0.140 |
Why?
|
| DNA Viruses | 1 | 2017 | 33 | 0.140 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 47 | 0.140 |
Why?
|
| Metapneumovirus | 1 | 2017 | 51 | 0.140 |
Why?
|
| Lectins, C-Type | 1 | 2017 | 71 | 0.140 |
Why?
|
| Blood Platelets | 1 | 2019 | 327 | 0.140 |
Why?
|
| Plasmids | 1 | 2018 | 510 | 0.140 |
Why?
|
| Receptors, Antigen | 1 | 2016 | 34 | 0.130 |
Why?
|
| Adolescent | 7 | 2025 | 19275 | 0.130 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 97 | 0.130 |
Why?
|
| Antigens, Viral | 1 | 2017 | 439 | 0.120 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 3339 | 0.120 |
Why?
|
| Female | 14 | 2025 | 66483 | 0.120 |
Why?
|
| Survival Analysis | 1 | 2018 | 1495 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2018 | 940 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 717 | 0.110 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2013 | 33 | 0.110 |
Why?
|
| Child | 6 | 2024 | 24367 | 0.110 |
Why?
|
| Hyponatremia | 1 | 2013 | 72 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 2011 | 51 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2024 | 293 | 0.090 |
Why?
|
| Cytomegalovirus | 2 | 2024 | 270 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 473 | 0.090 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 316 | 0.090 |
Why?
|
| HIV-1 | 1 | 2013 | 465 | 0.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 396 | 0.080 |
Why?
|
| Retrospective Studies | 6 | 2024 | 16312 | 0.080 |
Why?
|
| Cytokines | 3 | 2019 | 1292 | 0.070 |
Why?
|
| Myeloid Cells | 2 | 2018 | 101 | 0.070 |
Why?
|
| Registries | 1 | 2013 | 1424 | 0.070 |
Why?
|
| Bone Neoplasms | 1 | 2011 | 419 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 2498 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 882 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 2090 | 0.060 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2024 | 57 | 0.060 |
Why?
|
| Acetates | 1 | 2024 | 73 | 0.060 |
Why?
|
| Standard of Care | 1 | 2025 | 130 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 4795 | 0.060 |
Why?
|
| Adenocarcinoma | 1 | 2011 | 1021 | 0.050 |
Why?
|
| Medically Underserved Area | 1 | 2023 | 89 | 0.050 |
Why?
|
| Fas Ligand Protein | 1 | 2022 | 33 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 61 | 0.050 |
Why?
|
| Genes, myc | 1 | 2022 | 100 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2024 | 419 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 200 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 221 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Autografts | 1 | 2022 | 27 | 0.050 |
Why?
|
| Melphalan | 1 | 2022 | 49 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1544 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2023 | 244 | 0.050 |
Why?
|
| Minority Groups | 1 | 2023 | 247 | 0.050 |
Why?
|
| HIV Infections | 1 | 2013 | 1893 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2022 | 263 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 3554 | 0.050 |
Why?
|
| Rituximab | 1 | 2022 | 157 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1644 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 14 | 0.040 |
Why?
|
| Vidarabine | 1 | 2020 | 80 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2022 | 327 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 324 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2024 | 1184 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 79 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2019 | 227 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 330 | 0.040 |
Why?
|
| Antigens, CD7 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 555 | 0.040 |
Why?
|
| Epitopes | 1 | 2020 | 432 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 230 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2019 | 280 | 0.040 |
Why?
|
| Immunologic Memory | 1 | 2019 | 188 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 418 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 4349 | 0.040 |
Why?
|
| Granzymes | 1 | 2017 | 37 | 0.040 |
Why?
|
| Gene Editing | 1 | 2019 | 187 | 0.040 |
Why?
|
| Mice | 3 | 2019 | 17639 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 2017 | 50 | 0.040 |
Why?
|
| Cell Survival | 1 | 2019 | 806 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 65 | 0.030 |
Why?
|
| Adenoviruses, Human | 1 | 2017 | 81 | 0.030 |
Why?
|
| Herpesvirus 6, Human | 1 | 2017 | 58 | 0.030 |
Why?
|
| BK Virus | 1 | 2017 | 60 | 0.030 |
Why?
|
| Malocclusion | 1 | 1976 | 8 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2017 | 263 | 0.030 |
Why?
|
| Mandible | 1 | 1976 | 79 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 241 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 14007 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 293 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 502 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1915 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 757 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 681 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 6533 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 34086 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 231 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5145 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3421 | 0.030 |
Why?
|
| United States | 2 | 2021 | 10887 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2287 | 0.030 |
Why?
|
| Gene Expression | 1 | 2017 | 1561 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2019 | 1890 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 267 | 0.020 |
Why?
|
| Viral Load | 1 | 2013 | 384 | 0.020 |
Why?
|
| Etoposide | 1 | 2011 | 114 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 1032 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3062 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 5826 | 0.020 |
Why?
|
| Androgen Antagonists | 1 | 2011 | 119 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 1350 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 236 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1529 | 0.020 |
Why?
|
| Incidence | 1 | 2013 | 3138 | 0.020 |
Why?
|
| Infant | 1 | 2017 | 12466 | 0.010 |
Why?
|
| Veterans | 1 | 2013 | 1755 | 0.010 |
Why?
|
| Risk Factors | 1 | 2013 | 10265 | 0.010 |
Why?
|
| Cephalometry | 1 | 1976 | 33 | 0.010 |
Why?
|
| Rotation | 1 | 1976 | 51 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1976 | 120 | 0.010 |
Why?
|